Skip to main content

Table 2 Univariate and multivariate analyses of overall survival (n = 36 HLA-A*2402-matched patients)

From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Variables

 

Univariate analysis

Multivariate analysis

Hazard ratio

95% CI

p-value

Hazard ratio

95% CI

p-value

Age

≥65

2.150

1.058 to 4.396

0.0345

1.691

0.798 to 3.588

0.1689

Gender

male/female

1.193

0.581 to 2.436

0.6271

   

Stage

III/IV and Recurrence

0.743

0.275 to 1704

0.5033

   

Hb

≥13.2

0.724

0.350 to 1.515

0.3859

   

NLR

≥2.48

1.514

0.756 to 3.018

0.2384

   

CEA

≥5.3

1.791

0.879 to 3.813

0.1095

   

CA19-9

≥541

1.853

0.862 to 3.935

0.1120

   

IL-6

≥0.97

0.906

0.454 to 1.851

0.7816

   

PD-1+ CD4+

≥1.83

2.962

1.383 to 6.471

0.0054

2.546

1.138 to 5.765

0.0231

Tim-3+ CD4+

≥2.54

0.741

0.362 to 1.522

0.4091

   

PD-1+ CD8+

≥4.73

1.892

0.925 to 3.932

0.0803

   

Tim-3+ CD8+

≥4.58

0.881

0.429 to 1.799

0.7269

   

Treg

≥1.93

0.880

0.420 to 1.794

0.7268

   

MDSC

≥15.07

1.267

0.638 to 2.555

0.4981

   
  1. Statistical significant results are highlighted in bold letters
  2. Abbreviations: HLA human leukocyte antigen, CI confidence interval, Hb hemoglobin, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, NLR neutrophil lymphocyte ration, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived suppressor cell